Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Oral cavity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    315 result(s) found for: Oral cavity. Displaying page 9 of 16.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2022-000794-47 Sponsor Protocol Number: CTIN816A12201 Start Date*: 2023-01-13
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A randomized, multi-centric, placebo-controlled, participant and investigator-blinded study to evaluate the safety, tolerability and efficacy of TIN816 in adult patients at risk for acute kidney in...
    Medical condition: Acute kidney injury
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10069339 Acute kidney injury PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) EE (Trial now transitioned) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006514-37 Sponsor Protocol Number: DOAC-CO Start Date*: 2023-02-08
    Sponsor Name:Ente Ecclesiastico Ospedale Generale Regionale “F. Miulli”
    Full Title: Haemorrhagic risk of direct oral anticoagulants (DOACs) in patients undergoing oral surgery
    Medical condition: Patients on direct acting oral anticoagulants (DOACs) who are to undergo oral surgery.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007521 Cardiac arrhythmias HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003934-25 Sponsor Protocol Number: 3475-412 Start Date*: 2017-03-20
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous...
    Medical condition: Locally advanced head and neck squamous cell carcinoma (LA HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) AT (Completed) PL (Completed) CZ (Completed) BE (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002669-40 Sponsor Protocol Number: ALD518-CLIN-009 Start Date*: 2011-12-15
    Sponsor Name:Alder BioPharmaceuticals, Inc.
    Full Title: A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of ALD518 in the Reduction of Oral Mucositis in Subjects With Head and Ne...
    Medical condition: Oral Mucositis in subjects with head and neck cancer receiving concomitant chemotherapy and radiotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10028130 Mucositis oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001623-18 Sponsor Protocol Number: EGF102988 Start Date*: 2006-12-07
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or P...
    Medical condition: Resected Squamous Cell Carcinoma of the Head and Neck
    Disease: Version SOC Term Classification Code Term Level
    8.1 10041823 Squamous cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IE (Completed) GR (Completed) AT (Completed) SK (Completed) GB (Completed) DE (Completed) CZ (Completed) PT (Prematurely Ended) EE (Completed) HU (Completed) IT (Completed) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001704-37 Sponsor Protocol Number: CSPP100A2340 Start Date*: 2006-11-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 36 week, multicenter, randomized, double-blind, placebo- controlled, parallel-group, pilot study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular remodeling ...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) DE (Completed) SE (Completed) BE (Completed) CZ (Completed) HU (Completed) GB (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003589-10 Sponsor Protocol Number: D419LC00001 Start Date*: 2015-12-11
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic S...
    Medical condition: Adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who have not received prior systemic chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) GR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) BE (Completed) PL (Completed) AT (Completed) RO (Completed) FR (Completed) PT (Completed) BG (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004914-32 Sponsor Protocol Number: NL71558.041.19 Start Date*: 2020-03-12
    Sponsor Name:University Medical Center Utrecht
    Full Title: Sentinel lymph node (SLN) detection in early oral cancer using Gallium-68-Tilmanocept PET-CT
    Medical condition: The IMP will be used for the identification of sentinel lymph nodes in patients with early-stage oral squamous cell carcinoma and a clinically negative neck (T1-3N0M0).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10072873 Sentinel lymph node mapping LLT
    20.1 100000004848 10073554 Sentinel node biopsy LLT
    21.0 100000004864 10030961 Oral cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2020-002852-19 Sponsor Protocol Number: BO42533 Start Date*: 2021-03-10
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB PLUS TIRAGOLUMAB AND ATEZOLIZUMAB PLUS PLACEBO AS FIRST-LINE TREATMENT IN PATIENTS WITH RECURRENT/METASTATIC PD-L1 POSITIVE SQUAMOUS CELL ...
    Medical condition: Squamous cell carcinoma of the head and neck (SCCHN).
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10082179 Squamous cell carcinoma of head and neck metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000753-45 Sponsor Protocol Number: NAVIT-18 Start Date*: 2018-11-11
    Sponsor Name:NAVARRBIOMED-FUNDACION MIGUEL SERVET
    Full Title: Vitreretinal surgery with and without oral anticoagulants: surgical complications, visual results and perioperative thromboembolic events.
    Medical condition: Patients undergoing vitreoretinal surgery under treatment with oral anticoagulants
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002046-20 Sponsor Protocol Number: IOVHN12012 Start Date*: 2012-05-28
    Sponsor Name:ISTITUTO ONCOLOGICO VENETO
    Full Title: Role of SAMITAL in prevention and treatment of oral mucositis in patients treated with chemo-radiation (CT/RT)for head-and-neck squamous cell carcinomas. A double-blind, Phase 2 placebo controlled,...
    Medical condition: Head-and-neck cancer (Squamous cell carcinomas)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016842-22 Sponsor Protocol Number: MK01 Start Date*: Information not available in EudraCT
    Sponsor Name:photonamic GmbH & Co. KG
    Full Title: Evaluation of the suitability of PD L 506 for intraoperative visualisation of palpable and nonpalpable breast cancer tissue
    Medical condition: Breast cancer; palpable and non-palpable tumours of the female breast.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004266-25 Sponsor Protocol Number: 16-OBE001-005 Start Date*: 2017-02-24
    Sponsor Name:ObsEva S.A.
    Full Title: A phase 3, double-blind, randomized, placebo-controlled study to assess the safety and efficacy of a single oral administration of nolasiban to improve pregnancy rates following IVF or ICSI in Day ...
    Medical condition: Embryo implantation in women undergoing IVF or ICSI with Day 3 or Day 5 fresh embryo transfer cycles, in the context of Assisted Reproductive Technology (ART).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10073184 Embryo transfer LLT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed) DE (Completed) DK (Completed) BE (Completed) HU (Completed) EE (Completed) ES (Completed) FI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001456-21 Sponsor Protocol Number: B9991016 Start Date*: 2017-05-09
    Sponsor Name:Pfizer Inc.
    Full Title: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY (CISPLATIN PLUS DEFINITIVE RADIATION THERAPY) VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN...
    Medical condition: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Prematurely Ended) DE (Prematurely Ended) PL (Completed) AT (Prematurely Ended) ES (Prematurely Ended) IE (Completed) PT (Prematurely Ended) HU (Prematurely Ended) FR (Completed) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000781-23 Sponsor Protocol Number: GEN207 Start Date*: 2008-06-09
    Sponsor Name:Genmab A/S
    Full Title: An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination wi...
    Medical condition: Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum based Chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023860 Laryngeal squamous cell carcinoma stage III LLT
    9.1 10023861 Laryngeal squamous cell carcinoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004770-25 Sponsor Protocol Number: D7310C00001 Start Date*: 2020-12-11
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination with Cetuximab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head an...
    Medical condition: Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) GR (Completed) DE (Trial now transitioned) BE (Completed) AT (Completed) BG (Completed) PL (Completed) FR (Completed) PT (Completed) IT (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005820-17 Sponsor Protocol Number: 90111-24111 Start Date*: 2012-06-07
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Neoadjuvant BIBW 2992 followed by surgery in squamous cell carcinoma of the head and neck: an EORTC NOCI-HNCG window study.
    Medical condition: Squamous cell carcinoma of the head and neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender:
    Trial protocol: BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001153-27 Sponsor Protocol Number: PenVe Start Date*: 2019-02-22
    Sponsor Name:Guy's and St Thomas' NHS Foundation Trust
    Full Title: A feasibility study of a prospective randomised controlled trial comparing the use of open label pentoxifylline and tocopherol versus current standard of care for the prevention of fibrosis related...
    Medical condition: Osteoradionecrosis, trismus and dysphagia
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022117 - Injury, poisoning and procedural complications 10067352 Osteoradionecrosis PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10044684 Trismus PT
    20.0 10017947 - Gastrointestinal disorders 10013950 Dysphagia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-001296-20 Sponsor Protocol Number: MITOCET Start Date*: 2013-12-20
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Randomized Phase IV Trial to Compare Cetuximab with Concomitant Radiation Therapy with Concomitant Mitomycin-C and 5-FU with Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of The H...
    Medical condition: Locally advanced squamous cell carcinomas of head and neck
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000820-83 Sponsor Protocol Number: NNL-2017 Start Date*: 2017-07-03
    Sponsor Name:University of Oulu
    Full Title: Otitis Media and Nasopharyngeal Microbiome in Children. The change of nasopharyngeal microbiome and its role as a risk factor of otitis media. Streptococcus salivarius K12 and the change of nasop...
    Medical condition: We investigate role of microbiota as the risk factor of acute otitis media in children.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10033071 Otitis LLT
    20.1 100000004862 10069718 Bacterial colonization LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 17:43:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA